Prevention of hepatitis B

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 3, 2015, Pages

  Chang, Mei Hwei ^a   Chen, Ding Shinn ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; NUCLEOSIDE ANALOG; RECOMBINANT VACCINE; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN;

ACTIVE IMMUNIZATION; ARTICLE; CANCER PREVENTION; DRUG BLOOD LEVEL; DRUG EFFICACY; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; KIDNEY DISEASE; LIVER CELL CARCINOMA; MASS IMMUNIZATION; PASSIVE IMMUNIZATION; PATIENT COMPLIANCE; VACCINE FAILURE; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; LIVER NEOPLASMS; VACCINATION;

HEPATITIS B VIRUS;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULINS; LIVER NEOPLASMS; VACCINATION;

EID: 84923913790     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a021493     Document Type: Article

References (65)

1. Beasley RP. 2009. Rocks along the road to the control of HBVand HCC. Ann Epidemiol 19: 31-234.
2. Beasley RP, Hwang LY, Lin CC, Leu ML, Stevens CE, Szmu-ness W, Chen KP. 1982. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 146: 198-204.
3. Beasley RP, Hwang LY, Lin CC, Ko YC, Twu SJ. 1983a. Incidence of hepatitis among students at a university in Taiwan. Am J Epidemiol 117: 213-222.
4. Beasley RP, Hwang LY, Stevens CE, Lin CC, Hsieh FJ, Wang KY, Sun TS, Szmuness W. 1983b. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: Final report of a randomized double-blind, placebo-controlled trial. Hep-atology 3: 135-141.
5. Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, Chen CL. 1983c. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 2: 1099-1102.
6. Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. 1967. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 66: 924-931.
7. Blumberg BS, Sutnick AI, London WT.1969. Australia antigen and hepatitis. JAMA 207: 1895-1896.
8. Buynak EB, Roehm RR, Tytell AA, Bertland AU II, Lampson GP, Hilleman MR.1976. Vaccine against human hepatitis B. JAMA 235: 2832-2834.
9. Chang MH, Lee CY, Chen DS, Hsu HC, Lai MY. 1987. Fulminant hepatitis in children in Taiwan: The important role of hepatitis B virus. J Pediatr 111: 34-39.
10. Chang MH, Chen DS, Hsu HC, Hsu HY, Lee CY.1989. Maternal transmission of hepatitis B virus in childhood HCC. Cancer 64: 2377-2380.
11. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS, Taiwan Childhood Hep-atoma Study Group. 1997. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 336: 1855-1859.
12. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, et al. 2009. Decreased incidence of hepatocellular carcinoma in hepatitis B vac-cinees: A 20-year follow-up study. J Natl Cancer Inst 101: 1348-1355.
13. Chen DS. 2005. Ling-term protection ofhepatitis B vaccine: Lessons from Alaskan experience after 15 years. Ann Intern Med 142: 384-385.
14. Chen DS. 2009. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J Hepatol 50: 805-816.
15. Chen DS. 2011. Fighting against hepatitis B: Lessons from Taiwan. Hepatology 54: 381-392.
16. Chen DS, Hsu NHM, Sung JL, Hsu TC, Hsu ST, Kuo YT, Lo KJ, Shih YT. 1987. The Hepatitis Steering Committee, The Hepatitis Control Committee: A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen carrier-mothers. JAMA 257: 2597-2603.
17. Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, Chen DS. 1996. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA 276: 906-908.
18. Chen HL, Lin LH, Hu FC, Lee JT, Lin WT, Yang YJ, Huang FC, Wu SF, Chen SC, Wen WH, et al. 2012. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission ofHBV. Gastroenter-ology 142: 773-781.
19. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. 2013. Thirty-year outcomes of the National Hepatitis B Immunization Program in Taiwan. JAMA 310: 974-976.
20. Hall AJ. 2010. Boosters for hepatitis B vaccination? Need for an evidence-based policy. Hepatology 51: 1485-1486.
21. Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, Yue X, Wang GJ, Tang X, Fang ZX. 2011. A prospective and open-label study for the efficacy and safety of telbi-vudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 55: 1215-1221.
22. Hilleman MR. 1987. Yeast recombinant hepatitis B vaccine. Infection 15: 3-7.
23. Hsu HC, Lin GH, Chang MH, Chen HC. 1983. Association of hepatitis B surface antigenemia and membranous ne-phropathy in children in Taiwan. Clin Nephrol 20: 121-129.
24. Hsu HY, Chang MH, Chen DS, Lee CY, Sung JL. 1986. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: A study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 18: 301-307.
25. Hsu HM, Chen DS, Chuang CH, Lu JC, Jwo DM, Lee CC, Lu HC, Cheng SH, Wang YF, Wang CY. 1988. Efficacy of a mass hepatitis B vaccination program in Taiwan: Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA 260: 2231-2235.
26. Hsu HY, Chang MH, Ni YH, Chiang CL, Chen HL, Wu JF, Chen PJ. 2010. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. J Infect Dis 201: 1192-1200.
27. Hsu HY, Chang MH, Ni YH, Jeng YM, Chiang CL, Chen HL, Wu JF, Chen PJ. 2013. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant. J Infect Dis 207: 1047-1057.
28. Jan CF, Huang KC, Chien YC, Greydanus DE, Davies HD, Chiu TY, Huang LM, Chen CJ, Chen DS. 2010. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology51: 1547-1554.
29. Kao JH, Chen DS. 2008. Universal hepatitis B vaccination: Killing 2 birds with 1 stone. Am J Med 121: 1029-1031.
30. Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. 2001. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 139: 349-352.
31. Kappus MR, Sterling RK. 2013. Extrahepatic manifestations of acute hepatitis B virus infection. Gastroenterol Hepatol 9: 123-126.
32. Kruskall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D. 1992. The immune response to hepatitis B vaccine in humans: Inheritance patterns in families. J Exp Med; 175: 495-502.
33. Lavanchy D. 2012. Viral hepatitis: Global goals for vaccination. J Clin Virol 55: 296-302.
34. Lee GC, Hwang LY, Beasley RP, Chen SH, Lee TY. 1983. Immunogenicity of hepatitis B virus vaccine in healthy Chinese neonates. JInfect Dis 148: 526-529.
35. Lee CY, Huang LM, Chang MH, Hsu CY, Wu SJ, Sung JL, Safary A.1991. The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers. Pediatr Infect Dis J10: 299-303.
36. Lerkhachonsuk AA, Yip CH, Khuhaprema T, Chen DS, Piummer M, Jee SH, Toi M, Willailak S, Asian Oncology Summit. 2013. Cancer prevention in Asia: Resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol 14: 497-507.
37. Liao MT, Chang MH, Lin FG, Tsai IJ, Chang YW, Tsau YK. 2011. Universal hepatitis B vaccination reduces childhood hepatitis B virus-associated membranous nephropathy. Pediatrics 128: e600-e604.
38. Lin HH, Lee TY, Chen DS, Sung JL, Ohto H, Etoh T, Kawana T, Mizuno M. 1987. Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. JPediatr 111: 877-881.
39. Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. 2003. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 187: 134-138.
40. Lo KJ, Tsai YT, Lee SD, Yeh CL, Wang JY, Chiang BN, Wu TC, Yeh PS, Goudeau A, Coursaget P. 1985. Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan. Hepatogas-troenterology 32: 65-68.
41. Martínez-Sernandez V, Figueiras A. 2013. Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: A critical systematic review of scientific production. J Neurol 260: 1951-1959.
42. Maupas P, Chiron JP, Barin F, Coursaget P, Goudeau A, Perrin J, Denis F, Mair ID. 1981. Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet i: 289-292.
43. McMahon BJ, Bulkow LR, Singleton RJ, Williams J, Snowball M, Homan C, Parkinson AJ. 2011. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 54: 801-807.
44. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, Tsai KS, Chen DS. 2001. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 135: 796-800.
45. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, Kao JH, Lin YC, Chen HL, Hsu HY, et al. 2007. Two decades of universal hepatitis B vaccination in Taiwan: Impact and implication for future strategies. Gastroenterology 132: 1287-1293.
46. Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. 2012. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 57: 730-735.
47. Peto TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ. 2014. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program. BMC Infect Dis 14: 7.
48. Shiraki K, Yoshihara N, Sakurai M, Eto T, Kawana T. 1980. Acute hepatitis B in infants born to carrier mother with the antibody to hepatitis B e antigen. J Pediatr 97: 768-770.
49. Stevens CE, Beasley RP, Tsui J, Lee WC. 1975. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 292: 771-774.
50. Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN, Nair PV, Weissman JY, Krugman S. 1987. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 257: 2612-2616.
51. Su WJ, Liu CC, Liu DP, Chen SF, Huang JJ, Chan TC, Chang MH. 2012. Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan. J Infect Dis 205: 757-62.
52. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, Sadovsky R, Morrison JM, Kellner A. 1980. Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. NEngl J Med 303: 833-841.
53. Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH.1998. Hepatitis B surface antigenemia at birth: A long-term follow-up study. J Pediatr 133: 374-377.
54. Tsai YT, Lo KJ, Lee SD, Wang JY, Wu TC. 1984. Immunoprophylaxis against hepatitis B virus infection: A controlled trial in infants born to HBeAg-negative HBsAg carrier mothers in Taiwan. Chinese J Gastroenterol 1: 181-185.
55. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. 1982. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298: 347-350.
56. van Herck K, Vorsters A, Van Damme P. 2008. Prevention of viral hepatitis (B and C) reassessed. Best Pract Res Clin Gastroenterol 22: 1009-1029.
57. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. 2003. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 10: 294-297.
58. Wang CW, Wang LC, Chang MH, Ni YH, Chen HL, Hsu HY, Chen DS. 2005. Long-term follow-up of hepatitis B surface antibody levels in subjects receiving universal hepatitis B vaccination in infancy in an area of hyper-endemicity: Correlation between radioimmunoassay and enzyme immunoassay. Clin Diagn Lab Immunol 12: 1442-1447.
59. Wasley A, Miller JT, Finelli L, Wasley A, Miller JT, Finelli L. 2007. Surveillance for acute viral hepatitis—United States, 2005. MMWR Surveill Summary 56: 1-24.. 2007. Surveillance for acute viral hepatitis—United States, 2005. MMWR Surveill Summary 56: 1-24.
60. Wen WH, Chang MH, Zhao LL, Ni YH, Hsu HY, Wu JF, Chen PJ, Chen DS, Chen HL. 2013. Mother-to-infant transmission of hepatitis B virus infection: Significance of maternal viral load and strategies for intervention. J Hepatol 59: 24-30.
61. Whittle HC, Maine N, Pilkington J, Mendy M, Fortuin M, Bunn J, Allison L, Howard C, Hall A.1995. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 345: 1089-92.
62. Wichajarn K, Kosalaraksa P, Wiangnon S. 2008. Incidence of HCC in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev 9: 507-509.
63. Wu TW, Lin HH, Wang LY. 2013. Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology 57: 37-45.
64. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, et al. 2009. Lami-vudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: A multicentre, randomized, double-blind, placebo-controlled study. J ViralHepat 16: 94-103.
65. Yang JJ, Liu CC, Chen TJ, Lee MF, Chen SH, Shih HH, Chang MH. 2003. Role of hepatitis B immunoglobulin in infants born to hepatitis B e antigen-negative carrier mothers in Taiwan. Pediatr Infect Dis J 22: 584-588.